30 completed, 8 active not recruiting, 6 terminated, 6 unknown. 58 Phase 3, 17 Phase 2.
Follow Acute Lymphoblastic Leukemia: new trials by email Literature Review of Acute Lymphoblastic Leukemia trials Research Report on Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL targeted drug - Acute Lymphoblastic Leukemia | Phase 3 | Recruiting | Nanfang Hospital, Southern Medical University | 154 | 2025-10-01 | 2025-10-02 |
| A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia Randomization + Blinatumomab + chemotherapy, Randomization + Standard frontline T-ALL chemotherapy backbone, Randomization + Isatuximab + Standard frontline T-ALL chemotherapy backbone - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 1200 | 2025-05-06 | 2026-02-10 |
| Newly-diagnosed Pediatric T-cell ALL Protocol Venetoclax, Dasatinib, homoharringtonine - Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic | Phase 2 / Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 610 | 2025-03-11 | 2025-08-26 |
| Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis Conditioning regimen: Treosulfan 42 g/m2/course or total body irradiation 12 Gray/course, Etoposide 60 mg/kg , Fludarabine 150 - Biphenotypic Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 50 | 2024-07-10 | 2025-01-01 |
| Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis Baricitinib - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 / Phase 3 | Active not recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 150 | 2023-12-01 | 2024-08-23 |
| Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Aspiration, Busulfan - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 66 | 2023-03-15 | 2026-07-30 |
| Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia Blinatumomab - Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia | Phase 3 | Recruiting | Princess Maxima Center for Pediatric Oncology | 160 | 2022-12-15 | 2026-10-19 |
| Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis GVHD prevention: post-transplantation cyclophosphamide, abatacept, vedolizumab, calcineurin inhibitor - Acute Lymphoblastic Leukemia, Myeloblastic Leukemia | Phase 3 | Active not recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 56 | 2022-08-23 | 2023-09-28 |
| Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL Cladribine, Fludarabine - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 32 | 2022-01-01 | 2022-10-13 |
| SPARK-ALL: Calaspargase Pegol in Adults With ALL Calaspargase pegol (S95015) - Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Terminated | Institut de Recherches Internationales Servier | 42 | 2021-07-07 | 2026-10-29 |
| Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005) Efprezimod alfa, Placebo, Methotrexate - Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease | Phase 3 | Terminated | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 11 | 2021-01-05 | 2023-02-08 |
| Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia Tisagenlecleucel, Blinatumomab, Inotuzumab - Acute Lymphoblastic Leukemia | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2020-06-05 | 2020-07-09 | |
| An Open-Label Study of JZP-458 (RC-P) in Patients With Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL) IM JZP-458, IV JZP-458 - Acute Lymphoblastic Leukemia, Lymphoblastic Leukemia | Phase 2 / Phase 3 | Completed | Jazz Pharmaceuticals | 229 | 2019-12-27 | 2023-11-18 |
| Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test - Acute Myeloid Leukemia in Remission, Lymphoma in Remission | Phase 2 / Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 227 | 2019-09-16 | 2021-09-28 |
| An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Venetoclax - Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia | Phase 3 | Active not recruiting | AbbVie | 165 | 2019-09-06 | 2026-05-13 |
| HLA 10/10 Matched Unrelated Donor vs Haploidentical Allogenic Hematopoietic Stem Cell Transplantation Haplo donor stem cell transplantation, HLA 10/10 MUD stem cell transplantation - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 344 | 2018-08-01 | 2018-08-31 |
| Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 3 | Terminated | Kiadis Pharma | 63 | 2017-11-29 | 2022-05-24 |
| Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) Blinatumomab, Dexamthasone - Acute Lymphoblastic Leukemia | Phase 3 | Completed | Amgen | 121 | 2017-10-18 | 2023-02-08 |
| Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide - Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 352 | 2017-08-08 | 2026-10-05 |
| Phase III B in Acute Lymphoblastic Leukemia CTL019 - Acute Lymphoblastic Leukemia | Phase 3 | Completed | Novartis Pharmaceuticals | 69 | 2017-04-24 | 2021-07-21 |
Showing 20 of 58. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (58) · Leukemia, Myeloid, Acute (13) · Myelodysplastic Syndromes (12) · Leukemia, Biphenotypic, Acute (8) · Leukemia (7) · Hodgkin Disease (5) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (5) · Lymphoma (5) · Lymphoma, Non-Hodgkin (5) · Burkitt Lymphoma (4) · Multiple Myeloma (4) · Graft vs Host Disease (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (3) · Hematologic Neoplasms (2)
Hematologic Diseases (58) · Hemic and Lymphatic Diseases (58) · Immune System Diseases (58) · Immunoproliferative Disorders (58) · Leukemia, Lymphoid (58) · Lymphatic Diseases (58) · Lymphoproliferative Disorders (58) · Neoplasms by Histologic Type (58) · Neoplasms (57) · Leukemia (51) · Leukemia, Myeloid (16) · Bone Marrow Diseases (13) · Lymphoma (10) · Pathologic Processes (10) · Pathological Conditions, Signs and Symptoms (10)
Methotrexate (22) · Cytarabine (18) · Cyclophosphamide (17) · Dexamethasone (16) · Mercaptopurine (16) · Vincristine (15) · pegaspargase (15) · Daunorubicin (11) · Asparaginase (10) · Doxorubicin (10) · Etoposide (10) · merphos (10) · Calcium Dobesilate (9) · Prednisone (9) · azathiopurine (9)
Children's Oncology Group (8) · St. Jude Children's Research Hospital (5) · Assistance Publique - Hôpitaux de Paris (4) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (3) · Bristol-Myers Squibb (2) · Copenhagen University Hospital, Rigshospitalet (2) · Dana-Farber Cancer Institute (2) · Nanfang Hospital, Southern Medical University (2) · National Cancer Institute (NCI) (2) · Novartis Pharmaceuticals (2) · AbbVie (1) · Amgen (1) · Case Comprehensive Cancer Center (1) · Changzhou Jinyuan Pharmaceutical Manufacturing Co., Ltd. (1) · Fred Hutchinson Cancer Center (1)
United States (28) · Canada (15) · Australia (12) · China (9) · France (9) · Germany (9) · New Zealand (9) · Sweden (8) · Belgium (7) · Italy (7) · Puerto Rico (7) · Denmark (6) · Finland (6) · Netherlands (6) · Russia (6)
Anne L Angiolillo (2) · Kjeld Schmiegelow, M.D. (2) · Sima Jeha, MD (2) · Andrea Biondi (1) · Ardeshir Ghavamzadeh, MD (1) · Arja Harila-Saari, MD (1) · Asha Pillai, MD (1) · Betty Hamilton, MD (1) · Brenda Sandmaier (1) · Ching-Hon Pui, MD (1) · Daniel J. DeAngelo, MD, PhD (1) · Denis Claude Roy, Prof MD (1)
PMID 39121442, PMID 37890117, PMID 24970932, PMID 26590194, PMID 29284596, PMID 38446568, PMID 40315406, PMID 11675328, PMID 15226337, PMID 15247354, PMID 16155013, PMID 17366834, PMID 18358930, PMID 20850381, PMID 21220611, PMID 21846410, PMID 21943236, PMID 22037714, PMID 22074157, PMID 22086414, PMID 22265847, PMID 22323480, PMID 23140366, PMID 23244073, PMID 23358966, PMID 23678006, PMID 24428625, PMID 25087182, PMID 25418987, PMID 25749825, PMID 26124497, PMID 26265699, PMID 26735993, PMID 27292104, PMID 27451978, PMID 28258828, PMID 28660740, PMID 28687420, PMID 29020310, PMID 29330398, PMID 29381191, PMID 29518185, PMID 29727043, PMID 29812996, PMID 30626253, PMID 30709437, PMID 30920645, PMID 30978155, PMID 31188727, PMID 31248843
U10CA098543 (6), U10CA180886 (4), 2016 (2), 2014 (1), 2017 (1), F32CA141762 (1), P01CA018029 (1), P30CA015704 (1), P50GM115279 (1), R01CA090246 (1), R01CA140729 (1), R01CA174683 (1), R37CA036401 (1), U10CA021115 (1), U10CA095861 (1)